JP2009536155A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536155A5
JP2009536155A5 JP2009505472A JP2009505472A JP2009536155A5 JP 2009536155 A5 JP2009536155 A5 JP 2009536155A5 JP 2009505472 A JP2009505472 A JP 2009505472A JP 2009505472 A JP2009505472 A JP 2009505472A JP 2009536155 A5 JP2009536155 A5 JP 2009536155A5
Authority
JP
Japan
Prior art keywords
aliphatic
optionally substituted
compound according
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009505472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536155A (ja
JP5313875B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/009006 external-priority patent/WO2007120752A2/en
Publication of JP2009536155A publication Critical patent/JP2009536155A/ja
Publication of JP2009536155A5 publication Critical patent/JP2009536155A5/ja
Application granted granted Critical
Publication of JP5313875B2 publication Critical patent/JP5313875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009505472A 2006-04-12 2007-04-12 増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン Expired - Fee Related JP5313875B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79132706P 2006-04-12 2006-04-12
US60/791,327 2006-04-12
US83872006P 2006-08-18 2006-08-18
US60/838,720 2006-08-18
PCT/US2007/009006 WO2007120752A2 (en) 2006-04-12 2007-04-12 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2009536155A JP2009536155A (ja) 2009-10-08
JP2009536155A5 true JP2009536155A5 (https=) 2010-05-27
JP5313875B2 JP5313875B2 (ja) 2013-10-09

Family

ID=38544378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505472A Expired - Fee Related JP5313875B2 (ja) 2006-04-12 2007-04-12 増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン

Country Status (16)

Country Link
US (3) US7763629B2 (https=)
EP (1) EP2010542B1 (https=)
JP (1) JP5313875B2 (https=)
KR (1) KR101432316B1 (https=)
AR (1) AR060432A1 (https=)
AT (1) ATE542823T1 (https=)
AU (1) AU2007238690B2 (https=)
CA (1) CA2649324A1 (https=)
ES (1) ES2381212T3 (https=)
IL (1) IL194699A (https=)
MX (1) MX2008013110A (https=)
NO (1) NO20084747L (https=)
NZ (1) NZ571969A (https=)
RU (1) RU2441006C2 (https=)
TW (1) TW200808805A (https=)
WO (1) WO2007120752A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2010008459A1 (en) * 2008-06-23 2010-01-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
MX2011000026A (es) * 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
CA2773827A1 (en) * 2009-09-25 2011-03-31 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US8541418B2 (en) 2009-12-23 2013-09-24 Elan Pharmaceutical, Inc. Inhibitors of polo-like kinase
JP5850321B2 (ja) * 2010-02-10 2016-02-03 公立大学法人横浜市立大学 神経選択的転写抑制因子NRSFに特異的に結合するmSin3Bに結合する化合物の利用
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
US20120115848A1 (en) 2010-10-08 2012-05-10 Elan Pharmaceuticals, Inc. Inhibitors of Polo-Like Kinase
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並-咪唑並-吡啶並-二氮呯化合物
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
MD4300C1 (ro) * 2012-12-28 2015-03-31 Государственный Университет Молд0 Inhibitor al proliferării celulelor HepG2 în cancerul hepatic în bază de cloro-[2-fenil(piridin-2-il)metanon-4-(3-metoxifenil)tiosemicarbazono]nichel
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
SI3687996T1 (sl) 2017-09-27 2022-04-29 Incyte Corporation Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
MD3813800T2 (ro) 2018-06-29 2025-10-31 Incyte Corp Formulări de inhibitor al AXL/MER
CN109734809A (zh) * 2019-02-27 2019-05-10 南方科技大学 治疗性的人Plk1蛋白单克隆抗体及其制备方法
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP7545622B2 (ja) 2021-02-08 2024-09-05 江蘇星盛新輝医薬有限公司 5,6-ジドヒロチエノ[3,4-h]キナゾリン系化合物
EP4157849A4 (en) * 2021-08-10 2024-12-11 Uppthera, Inc. NOVEL PLK1 DEGRADATION-INDUCING COMPOUND

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1409487A1 (en) * 1999-09-15 2004-04-21 Warner-Lambert Company Llc Pteridinones as kinase inhibitors
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
KR20120032574A (ko) 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
RU2351586C2 (ru) * 2002-10-03 2009-04-10 Таргеджен, Инк. Васкулостатические агенты и способы их применения
CA2528975A1 (en) 2003-06-10 2004-12-16 Pfizer Inc. Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
GB0412874D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel

Similar Documents

Publication Publication Date Title
JP2009536155A5 (https=)
JP2009533452A5 (https=)
US8642602B2 (en) Method of inhibiting fibrogenesis and treating fibrotic disease
TWI556820B (zh) Hsp90抑制劑之組合
CN110305109B (zh) 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
ES2400070T3 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
JP2021536458A (ja) アリール炭化水素レセプター・アンタゴニスト及び使用方法
JP6889101B2 (ja) グルタミナーゼ阻害剤の結晶形態
TW201823232A (zh) 含有取代的吡啶酮之三環化合物及其使用方法
RU2008144584A (ru) 4,5-дигидро-[1,2,4]триазоло[4,3-f]птеридины в качестве ингибиторов протеинкиназы plk1 для лечения пролиферативных заболеваний
JP2011521968A5 (https=)
TW201107331A (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
US20240189289A1 (en) Inhibitors of ephb3 signaling
JP2010535211A (ja) 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物
US20150218148A1 (en) Benzothiazole Or Benzoxazole Compounds As Sumo Activators
WO2025157289A1 (zh) 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
JP2013501808A (ja) アポトーシスを促進し、かつ転移を阻害する方法
EP4433597A1 (en) Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease
JP2022501390A (ja) 化合物及びその用途
US20180326121A1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential
AU2014280354A1 (en) Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor
US20130324520A1 (en) Rxrg modulators for the treatment of cancer
CN112574176B (zh) 一种杂芳基类化合物及其应用
CN112105620A (zh) 用于治疗肺癌的tlr7激动剂及其药物组合
WO2025157288A1 (zh) 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物